Sparx Biopharmaceutical Corp. has received FDA approval of its IND application for SPX-303, a first-in-class anti-LILRB2/PD-L1 bispecific antibody drug candidate.
Sparx Group has formed a strategic alliance with Arovella Therapeutics Ltd. for the development of a CLDN18.2-chimeric antigen receptor (CAR)-invariant natural killer T (iNKT) cell therapy.
